Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): randomized, double-blind phase 3a trial – The Lancet

by



[ad_1]

  1. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): double-blind, randomized, phase 3a trial The Lancet
  2. Todd Hobbs, MD: Oral Semaglutide vs. Empagliflozin MD Magazine
  3. View full coverage on Google News

[ad_2]

Source link